Baseline demographics
| Characteristic | Full analysis set | |
| Esomeprazole 20 mg (n=330) | Placebo (n=321) | |
| Age (years) | ||
| Mean (SD) | 42.7 (13.1) | 44.4 (13.0) |
| Female, n (%) | 190 (57.6) | 177 (55.1) |
| Race, n (%) | ||
| White | 208 (63.0) | 219 (68.2) |
| Black/African-American | 112 (33.9) | 99 (30.8) |
| Asian | 0 (0) | 1 (0.3) |
| Native Hawaiian/Pacific Islander | 1 (0.3) | 0 (0) |
| American Indian/Alaskan native | 4 (1.2) | 0 (0) |
| Other | 5 (1.5) | 2 (0.6) |
| Run-in days with heartburn, mean (SD) | ||
| Full analysis set | 5.7 (1.8) | 5.8 (1.8) |
| More frequent*† | 7.0 (1.0) | 7.0 (1.0) |
| Less frequentठ| 4.0 (1.0) | 3.9 (1.0) |
| Run-in heartburn intensity score, mean (SD) | ||
| Full analysis set | 1.1 (0.48) | 1.1 (0.52) |
| More frequent*† | 1.4 (0.42) | 1.4 (0.46) |
| Less frequentठ| 0.8 (0.30) | 0.7 (0.30) |
*More frequent heartburn defined as 6 or more days of heartburn during the run-in period.
†Esomeprazole: n=185; placebo: n=191.
‡Less frequent heartburn defined as fewer than 6 days of heartburn during the run-in period.
§Esomeprazole: n=145; placebo: n=130.